President and Chief Executive Officer and Chairman of the Board · Elicio Therapeutics, Inc. (ELTX)

Jay Venkatesan

A named executive officer of Elicio Therapeutics in every fiscal year CompBrief holds from FY2020 to FY2021. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2021

$2,539,199

Salary $587,100Stock awards $0

FY2020: $1,394,398

1st of 3 named executive officers at Elicio Therapeutics by FY2021 total.

3 named officers on file for Elicio Therapeutics, FY2021

Jay Venkatesan’s pay file — $29

  • 2 fiscal years of pay, line by line
  • 1 equity grant, each cited to its filing

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Elicio Therapeutics’s whole pay program stands against its peers

  • Elicio Therapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on ELTX→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 27, 2022 (DEF 14A). Insider transactions since that proxy, current to 2026-11-21.

Free

Get Jay Venkatesan’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Jay Venkatesan compensation by year

Elicio Therapeutics Summary Compensation Table · all 2 fiscal years held
In US dollars, as Elicio Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2020FY2021
Salary$570,000$587,100
Bonus$194,800$0
Stock awards$0$0
Option awards$629,598$1,952,099
Non-equity incentive$0$0
Pension and deferred compensation$0$0
All other$0$0
Total$1,394,398$2,539,199

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Elicio Therapeutics, Inc. DEF 14A filed April 27, 2022, accession 0001601485-22-000026, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Elicio Therapeutics, Inc. filed document, accession 0001601485-22-000026. Every figure is read from that document and cited to the page and table it appears in. Filed April 27, 2022.

$1.4M
$2.5M
FY20
FY21
SalaryBonusOption awards

Equity holdings

unvested awards at FY2021 year-end
TypeUnvested unitsValue at year-endExercise price
RSU92,755$268,990—
Option141,645—$16.00
Option77,792—$7.77

Per the Outstanding Equity Awards at Fiscal Year-End table in Elicio Therapeutics, Inc.'s FY2021 proxy; value at the fiscal year-end close, as the company printed it.

Insider transactions since the last proxy

16 Form 4 lines since the FY2021 proxy (filed April 27, 2022)
current to 2026-11-21 · updated nightly
DateTransactionPlanSharesPriceHeld after
2026-08-31Grant or award derivative—21,750$0.0021,750
2025-05-19Grant or award derivative—7,900$0.007,900
2024-11-26Exercise derivative—50,000$0.000
2024-11-26Exercise—50,000$0.01179,581
2024-11-21Grant or award derivative—4,100$0.004,100
2024-06-28Purchase derivative—50,000$0.0050,000
2024-06-28Purchase derivative—50,000$0.0050,000
2024-06-28Purchase derivative—50,000$4.9950,000

The 8 most recent of 16 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →

Elicio Therapeutics’s named executive officers, FY2021

as the company reported each
Named executive officerRoleFY2021 total
Jay Venkatesan · this pagePresident and Chief Executive Officer and Chairman of the Board$2,539,199
Itzhak GoldbergExecutive Chairman and Chief Scientific Officer$1,247,881
John NeylanExecutive Vice President, Chief Medical Officer and Head of Research ( 6)$1,232,513

Board service

Elicio Therapeutics board · FY2021–FY2025
Director compensation in US dollars, as Elicio Therapeutics reports it. Most recent year first; a dash means the company reported no figure in that column.
Fiscal yearCash feesStock awardsOption awardsOtherTotal
FY2025$40,000—$37,758—$77,758
FY2024$40,000$0$17,148$0$57,148
FY2023$23,333—$22,427—$45,760
FY2021—————

Each year as the company reported it in Elicio Therapeutics's director compensation table. Totals are the company's own disclosed totals.

How this board is paid

Company policy: Elicio Therapeutics pays directors a $40,000 cash retainer. As stated in Elicio Therapeutics's FY2025 proxy.

The full Elicio Therapeutics compensation record

free company brief

This page is one person within Elicio Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Elicio Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Jay Venkatesan's compensation dossier · One-time report. No refunds.